Cholesterol and lipoproteins

Heart disease is the single biggest barrier to a long life, and the cholesterol that drives it is widely misunderstood. What ages your arteries is not the cholesterol number on one panel — it's the lifelong number of cholesterol-carrying particles your blood vessels have been exposed to. The famous cholesterol "paradoxes" don't overturn that; they just confuse people who read a snapshot as if it were the whole movie.

Cholesterol itself is not a villain — it is an essential building block of every cell membrane and the raw material for hormones, vitamin D, and bile. The problem is transport. Cholesterol does not dissolve in blood, so the body wraps it in particles called lipoproteins. Some of those particles get trapped in artery walls and start the slow, decades-long process of atherosclerosis. Understanding which particles matter, and why, explains nearly every cholesterol-related recommendation on the rest of this site — and dissolves most of the apparent contradictions that circulate online.

Particles, not cholesterol — why apoB is the real signal

Strong. The standard lipid panel reports the mass of cholesterol carried inside particles: total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol, and triglycerides. But atherosclerosis is not caused by cholesterol mass — it is caused by the number of artery-penetrating particles. Every atherogenic particle (LDL, its precursors VLDL and IDL, and lipoprotein(a)) carries exactly one molecule of apolipoprotein B (apoB) on its surface. Measuring apoB therefore counts those particles directly, and large analyses rank it above non-HDL cholesterol, with LDL-C the least reliable of the three.^[1]

This matters because the cholesterol number and the particle count often disagree. When particles are small, dense, and cholesterol-depleted — the pattern seen in insulin resistance and metabolic syndrome — LDL-C can look reassuringly normal while the particle count is dangerously high. In large primary-prevention cohorts, when LDL-C and apoB disagree, cardiovascular risk tracks apoB, not LDL-C.^[2] Roughly a quarter of adults are discordant, which is why apoB is the better individual risk marker. The practical targets, testing cadence, and treatment ladder live in lipid management and midlife labs; this page is about the underlying biology.

The biology: retention and cumulative exposure

Strong. Atherosclerosis is not fat passively clogging a pipe. It is an immune-inflammatory response to apoB particles becoming trapped in the artery wall. Once retained beneath the vessel lining, the particles oxidise, recruit immune cells (monocytes that mature into macrophages), and those macrophages engorge themselves on the oxidised lipid to become "foam cells." Foam cells die, forming the soft necrotic core of a plaque. This connects cholesterol directly to one of the integrative hallmarks of aging — chronic, low-grade inflammation.

The single most important consequence is that risk is cumulative. Each particle that crosses the artery wall has some probability of being trapped, so total plaque burden is the particle count multiplied by the years of exposure — an area under the curve, not a snapshot. This is why the question is never "is my cholesterol high right now?" but "how high has my particle count been, for how long?" It is also why lowering apoB earlier in life buys far more than the same reduction started in late middle age: genetic studies that mimic lifelong low LDL show several-fold greater benefit per unit lowered than late-life drug treatment.^[3]

Lipoprotein(a): the genetic wildcard

Strong / causal. Lipoprotein(a), written Lp(a), is an LDL-like particle with an extra protein tail (apolipoprotein(a)) that structurally resembles plasminogen, the molecule that dissolves clots. That makes Lp(a) simultaneously atherogenic, pro-thrombotic, and pro-inflammatory — meaningfully more dangerous, particle for particle, than ordinary LDL. Roughly one in five people inherit high levels, which are set genetically, stable for life from early childhood, and essentially unmoved by diet, exercise, weight loss, or statins.

Because it is invisible to lifestyle change and to a standard panel, the recommendation is simple: measure it once in a lifetime to know whether you carry this risk. What to do about an elevated result — intensify every other modifiable factor, with targeted Lp(a)-lowering drugs now in late-stage trials — is covered in lipid management.

The paradoxes that confuse people

Three findings get cited as if they overturn the apoB story. None of them do — but each is real and worth understanding, because the explanation is the same in all three: a single late-life or short-term snapshot is not the same thing as lifelong cumulative exposure.

Very high HDL is not protective

Moderate (observational). HDL was long called "good cholesterol" because it carries cholesterol away from tissues back to the liver. The reality is a U-shaped curve: both low and very high HDL associate with higher mortality. Cardiovascular and all-cause death rise once HDL cholesterol exceeds roughly 2.3 mmol/L (90 mg/dL) in men and about 2.8–3.0 mmol/L (110–116 mg/dL) in women.^[4] The extra risk at the high end appears in non-diabetic men too, independent of the usual confounders.^[5]

Very high HDL often signals dysfunctional particles that have lost their anti-inflammatory and cholesterol-offloading capacity, or is driven by heavy alcohol intake (which carries its own mortality). Crucially, drugs that raise HDL have repeatedly failed to reduce events in randomised trials. The lesson: HDL is a marker of metabolic state, not a lever to pull — and the old idea that alcohol's HDL-raising effect protects the heart has collapsed under genetic analysis.

Low cholesterol in the very old

Moderate — reverse causation. In people in their late 80s, 90s, and beyond, higher total cholesterol and LDL-C often associate with lower mortality — the opposite of the relationship in midlife. This "cholesterol paradox" shows up even in longevity hot spots such as Sardinia.^[6] The dominant explanation is reverse causation: serious illness, frailty, malnutrition, and occult cancer all lower cholesterol, so low cholesterol in the very old is frequently a marker of approaching decline rather than its cause.^[7]

This does not contradict the lifelong story. Genetic studies — which capture decades of exposure rather than one frail year — consistently show that a lifelong predisposition to lower LDL-C and apoB extends lifespan and lowers cardiovascular risk.^[8] Low cholesterol in a 95-year-old can mean illness; low cumulative apoB across a lifetime means protected arteries. They are not the same measurement. See Blue Zones for how to read longevity-population data without over-fitting.

Keto and the Lean-Mass Hyper-Responder

Weak / preliminary — flag the uncertainty. A specific group of lean, fit, metabolically healthy people who adopt a ketogenic (very-low-carbohydrate) diet develop a striking triad: very high LDL-C (often above 4.9 mmol/L / 190 mg/dL, sometimes far higher), high HDL, and low triglycerides. These are the "Lean-Mass Hyper-Responders." The proposed mechanism — the Lipid Energy Model — is that with carbohydrate scarce, a lean liver ships large amounts of fat to muscle for fuel via triglyceride-rich particles that remodel into many LDL particles; the leaner the person, the higher the LDL spike.

The provocative data come from the KETO-CTA study: hyper-responders maintaining a mean LDL-C around 7.0 mmol/L (272 mg/dL) for several years showed no greater coronary plaque burden than a comparison group with far lower LDL-C, and over one year of follow-up the change in plaque was predicted by existing plaque, not by apoB or LDL-C — summarised as "plaque begets plaque, but apoB does not" in this phenotype.^[9] That is genuinely surprising and an active area of debate.^[10] But the cohorts are young, the windows are short (a few years against a disease that takes decades), and no long-term outcome data exist yet. The honest position is uncertainty, not reassurance: hyper-responders who want to stay in ketosis but not gamble on unproven long-term risk can lower apoB with a cholesterol-absorption inhibitor (ezetimibe).

What actually moves your lipids

Moderate. Lifestyle reliably improves the lipid profile, but the effect sizes are modest — for someone with genuinely high apoB, pharmacology does the heavy lifting. The lifestyle levers still matter because they act for decades and improve much more than lipids.

Diet. The dominant dietary lever is substitution: replacing saturated fat with polyunsaturated fat (and high-quality carbohydrate) lowers LDL-C and cuts cardiovascular events by roughly 17% in pooled trials, whereas swapping it for refined carbohydrate does little.^[11] Dietary cholesterol itself (eggs, shellfish) has a weak effect in most people, because the liver compensates — modern guidelines dropped the old numeric limit.^[12] Detail lives in dietary fats and dietary patterns.
Exercise. Aerobic training shifts the whole panel modestly and, more importantly, lowers apoB and improves particle quality even when LDL-C barely moves.^[13] Resistance training mainly lowers triglycerides; combining the two is best.^[14] Even prolonged sitting matters — it collapses the muscle enzyme (lipoprotein lipase) that clears triglycerides from the blood.
Sleep and circadian rhythm. Lipid abnormalities follow a U-shaped curve with sleep duration, worst at both short and long ends.^[15] Night-shift work independently raises total cholesterol, even in people who report sleeping well — keeping a regular circadian rhythm is part of lipid metabolism, not separate from it.^[16]
Stress. Acute psychological stress transiently raises cholesterol and triglycerides through the stress-hormone axis, and chronic stress sustains the pattern; structured stress reduction modestly improves the profile.

How clinicians turn all of this into a personal plan — formal cardiovascular-risk scoring (such as Europe's SCORE2, which estimates 10-year risk of fatal and non-fatal events), apoB targets by risk tier, and when drugs are warranted — sits in lipid management. The unifying principle is "lower and earlier is better" for apoB across the whole adult lifespan.

What's overrated

Chasing a high HDL. It is a marker, not a target; very high levels can signal dysfunction, and HDL-raising drugs don't improve outcomes.
Fixating on a single LDL-C reading. One number on one day says little. Lifelong apoB exposure is the quantity that builds plaque.
Dietary-cholesterol panic. For most people, eggs and shellfish move blood cholesterol little; the dietary pattern and saturated-fat substitution dominate.
Reading the paradoxes as a green light. Low cholesterol in the frail elderly and the keto hyper-responder findings are interesting nuances at the edges — not licence for a healthy midlife adult to ignore a high apoB.